UK Sets Out New Blueprint for Regulating AI in Healthcare

The UK is preparing to rethink how artificial intelligence should be regulated inside healthcare, with a new set of recommendations calling for closer monitoring of AI medical tools long after they reach hospitals and clinics.

The National Commission into the Regulation of AI in Healthcare has published a regulatory blueprint built around a problem that traditional medical-device rules were never really designed for: AI can change after deployment. An algorithm may perform well during testing, enter clinical use, encounter a different patient population and begin behaving differently. Some systems may also receive frequent updates or become more autonomous over time.

The Commission wants regulation to follow that reality rather than treating approval as the finish line. Its recommendations cover staged regulatory authorisation, post-market monitoring, clearer rules for AI-enabled medical devices, greater transparency and stronger responsibility across the healthcare system.

UK Wants AI Regulation to Continue After Approval

Traditional medical-device regulation places considerable weight on evidence collected before a product enters the market, but AI complicates that model. Some systems are highly context-sensitive, while others may change after software updates or perform differently across hospitals and patient groups. A model that appears reliable during a controlled evaluation may not necessarily behave in exactly the same way once it enters routine clinical use.

The Commission argues that regulators therefore need to pay much more attention to evidence gathered after deployment. Its recommendations call for the Medicines and Healthcare products Regulatory Agency, or MHRA, and its partners to combine pre-market evidence with stronger post-market surveillance. Real-world monitoring could become particularly important for adaptive AI systems where uncertainty cannot be completely eliminated before launch.

Staged Approval Could Give AI Medical Tools a Different Route to Market

One of the more notable proposals is a move toward staged or continuous regulatory authorisation. Instead of assuming that a single approval decision can cover an AI product indefinitely, regulators could allow systems to progress through different stages as developers gather more evidence about safety, performance and reliability.

That approach could create a more practical route for promising healthcare AI. Developers would have more room to prove how their technology works in real clinical environments, while regulators would retain oversight as evidence accumulates. The Commission has pointed to real-time monitoring and staged authorisation as areas worth developing further as AI medical devices become more capable and more autonomous.

Hospitals Could Play a Bigger Role in AI Safety Monitoring

Hospitals and healthcare providers may also become a bigger part of the regulatory process. They could provide important information about what happens once AI enters everyday clinical practice, including performance problems, unexpected behaviour, inaccurate recommendations or incidents that could affect patient care.

This matters because laboratory benchmarks only tell part of the story. Clinical environments vary significantly, patient populations are different and workflows are rarely identical between hospitals. Even the way clinicians interact with an AI recommendation can influence the final outcome. A stronger reporting system could give regulators a clearer view of how AI performs outside controlled evaluations and help identify problems before they spread across the healthcare system.

MHRA Could Rewrite Rules for AI Medical Devices

The Commission also wants the UK to modernise its existing medical-device regulations. One recommendation calls on the MHRA to review current rules and create a framework better suited to software and AI-enabled medical devices.

Part of that work involves answering a basic but increasingly important question: when does an AI product actually become a medical device? Not every piece of software used inside healthcare performs a medical function. Administrative tools, general wellness applications and some decision-support systems may sit outside traditional medical-device regulation. Clearer definitions could help developers understand their obligations earlier while allowing regulators to concentrate on technologies that present genuine clinical risks.

Risk Could Matter More Than the AI Label

The recommendations suggest that regulation should focus more heavily on risk rather than treating every AI healthcare product in the same way. The Commission proposes a classification approach that considers clinical risk, potential patient benefit, the product lifecycle and alignment with international regulatory systems.

That distinction is likely to become more important as AI platforms combine administrative tools, clinical decision support, diagnostics and other functions inside a single product. Regulators may eventually focus on the individual functions that influence medical decisions rather than applying the same level of scrutiny to every feature inside an AI platform.

AI Airlock Is Already Testing the Regulatory Model

The UK has already started testing some of these ideas through the MHRA’s AI Airlock regulatory sandbox. The programme allows developers, regulators and healthcare partners to evaluate AI medical devices in controlled environments while examining difficult regulatory questions.

Its second phase ran from April 2025 to May 2026 and included technologies covering areas such as AI-powered clinical note-taking, cancer diagnostics, eye-disease detection and support for obesity treatment. The programme has given regulators a clearer picture of where existing rules work, where they create uncertainty and where new approaches may be needed.

Patients Are Part of the AI Regulation Debate

Patient trust is also central to the recommendations. Research published alongside the Commission’s work found that accuracy remains a major public priority, while human oversight continues to matter when AI is used in healthcare.

The wider discussion also points toward proportional regulation and the principle that AI should not produce worse outcomes for specific groups of patients. That makes transparency more than just a policy detail. Patients increasingly encounter AI indirectly through imaging analysis, diagnostic support, clinical documentation and systems that help professionals make decisions. Clear explanations about how AI influences care could become an important part of maintaining public confidence.

Why the UK AI Healthcare Framework Matters

Healthcare AI is now entering a difficult stage. The technology is no longer experimental enough to remain outside hospitals, but it is changing too quickly for regulatory systems that were designed around relatively static medical devices.

That is the gap the UK is trying to close. Continuous monitoring, staged authorisation and clearer responsibility could give developers more room to innovate without assuming that regulatory approval means oversight stops. Regulation could also become part of the UK’s wider strategy to position itself as a major hub for healthcare AI development.

The real challenge will be implementation. Hospitals will need the technical capability to monitor AI systems, developers will need predictable requirements and regulators will need enough expertise and data to recognise performance problems as they emerge. The recommendations provide a direction, but turning them into day-to-day healthcare regulation will be the harder part.

What Happens Next?

The Commission’s report contains 44 recommendations covering regulation across the lifecycle of AI-enabled healthcare technologies. The MHRA is expected to consider those proposals as it continues developing its approach to AI medical-device regulation.

The broader direction is already becoming clear. The UK does not want healthcare AI regulation to end when software receives approval. For adaptive and continuously evolving systems, approval may increasingly become the beginning of regulatory oversight rather than the end.